- Companies
- DSM-Firmenich
DSM-Firmenich Valuation Multiples
DSM-Firmenich is valued at $27B as of September 2026, a 2.8x revenue multiple. In the last 12 months, DSM-Firmenich revenue was $12B and DSM-Firmenich EBITDA was $2.2B.
DSM-Firmenich Overview
About DSM-Firmenich
DSM-Firmenich is a global science-based company formed in 2023 through the merger of DSM, a Dutch nutrition, health, and sustainable living player, and Switzerland-based Firmenich, the third-largest player in the flavor and fragrance market. The company serves a wide range of end-consumer markets providing nutrition solutions ranging from medical and early-life nutrition, fragrances for personal-, home-, and laundry-care brands, prestige perfumes, and other ingredients for food and beverage, home, and personal care. DSM-Firmenich has nearly 30,000 employees, with more than 2,000 scientists and engineers spread across 15 research and development facilities.
Founded
2022
HQ
Employees
27.0K
Website
Sectors
Financials (LTM)
EV
$33B
Valuation Multiples
Start free trialDSM-Firmenich Financials
DSM-Firmenich reported last 12-month revenue of $12B and EBITDA of $2.2B.
In the same LTM period, DSM-Firmenich generated $4.9B in gross profit, $2.2B in EBITDA, and $687M in net income.
Revenue (LTM)
DSM-Firmenich P&L
In the most recent fiscal year, DSM-Firmenich reported revenue of $10B and EBITDA of $1.8B.
DSM-Firmenich is unprofitable as of last fiscal year, with gross margin of 39%, EBITDA margin of 17%, and net margin of (12%).
Financial data powered by Morningstar, Inc.
DSM-Firmenich Stock Performance
DSM-Firmenich has current market cap of $27B, and enterprise value of $33B.
Market Cap Evolution
DSM-Firmenich's stock price is $111.46.
DSM-Firmenich share price increased by 0.2% in the last 30 days, and by 31.0% in the last year.
DSM-Firmenich has an EPS (earnings per share) of $-5.03.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $33B | $27B | -0.0% | 0.2% | 17.7% | 31.0% | $-5.03 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialDSM-Firmenich Valuation Multiples
DSM-Firmenich trades at 2.8x EV/Revenue multiple, and 14.8x EV/EBITDA.
EV / Revenue (LTM)
DSM-Firmenich Financial Valuation Multiples
As of September 29, 2026, DSM-Firmenich has market cap of $27B and EV of $33B.
DSM-Firmenich has a P/E ratio of 39.7x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified DSM-Firmenich Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


DSM-Firmenich Margins & Growth Rates
DSM-Firmenich grew revenue by 2% and EBITDA by 13% in the last fiscal year.
In the most recent fiscal year, DSM-Firmenich reported gross margin of 39%, EBITDA margin of 17%, and net margin of (12%).
DSM-Firmenich Margins
DSM-Firmenich Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
DSM-Firmenich Operational KPIs
DSM-Firmenich's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.
DSM-Firmenich's Rule of 40 is 21% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
DSM-Firmenich's Rule of X is 25% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
DSM-Firmenich Competitors
DSM-Firmenich competitors include OMV, Qnity Electronics, Ningxia Baofeng Energy Group, Novonesis, PPG, Ems-Chemie, Wanhua Chemical, International Flavors & Fragrances, Rongsheng Petro Chemical and Dow.
Most DSM-Firmenich public comparables operate across Chemicals.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $28B | $5.7B | 1.4x | 1.2x | 6.7x | 4.3x | |||
| $4.8B | $1.4B | 6.2x | 5.4x | 21.0x | 18.0x | |||
| $7.2B | $2.6B | 3.9x | 3.4x | 11.0x | 8.1x | |||
| $4.7B | $1.6B | 7.0x | 6.6x | 21.4x | 17.6x | |||
| $16B | $2.7B | 1.9x | 1.8x | 11.2x | 10.5x | |||
| $2.4B | $744M | 9.5x | 9.3x | 30.1x | 28.5x | |||
| $30B | $5.2B | 1.6x | 1.4x | 9.3x | 7.6x | |||
| $11B | $779M | 2.5x | 3.2x | 35.4x | 15.9x | |||
This data is available for Pro users. Sign up to see all DSM-Firmenich competitors and their valuation data. Start Free Trial | ||||||||
Acquisitions by DSM-Firmenich
DSM-Firmenich has acquired 2 companies to date.
Last acquisition by DSM-Firmenich was on April 19th 2023. DSM-Firmenich acquired Adare Biome for $297M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by DSM-Firmenich
| Description | Adare Biome is a biotechnology firm based in Barcelona, Spain, specializing in microbiome-based postbiotics for human and animal health applications. The company develops targeted microbial solutions to modulate gut health, immune responses, and metabolic functions using proprietary strains isolated from natural sources. Adare Biome partners with pharmaceutical and nutraceutical companies to deliver clinical-stage products addressing conditions like inflammatory bowel disease and obesity. Founded in 2019 as a spin-off from Adare Pharmaceuticals, it leverages advanced fermentation and encapsulation technologies for stable, scalable postbiotic formulations. | DSM, formally Koninklijke DSM N.V. or Royal DSM, was a Dutch multinational active in health, nutrition and materials, listed on Euronext Amsterdam. The Dutch state formed it in 1902 to mine coal reserves in southern Limburg, and its name comes from Dutch State Mines; by the time the last mine closed in 1973 it had diversified into commodity chemicals and petrochemicals. It later concentrated on nutritional and specialty food ingredients and performance materials such as engineering plastics and Dyneema fibre, earning revenue from product sales to food, feed, pharmaceutical and industrial customers. At the end of 2017 DSM employed 21,054 people in about 50 countries, and it posted net sales of €8.632 billion in 2018 and €9.204 billion in 2021. In 2013 it contributed its DSM Pharmaceutical Products business to a new contract manufacturer formed with JLL Partners around Patheon, keeping a 49% stake. In May 2023 DSM merged with the Swiss company Firmenich to form dsm-firmenich. |
| HQ Country | ||
| HQ City | Paris | Heerlen |
| Deal Date | 19 Apr 2023 | 3 Apr 2023 |
| Valuation | $297M | undisclosed |
| EV/Revenue | ||
| EV/EBITDA | ||
This data is available for Pro users. Sign up to see all DSM-Firmenich acquisitions and their M&A valuation multiples. Start Free Trial | ||
Investments by DSM-Firmenich
DSM-Firmenich has invested in 1 company to date.
Latest investment by DSM-Firmenich was on March 13th 2024. DSM-Firmenich invested in Cynomys in their $2M Seed round (EV/Revenue multiple available to Pro users).
Latest Investments by DSM-Firmenich
| Description | Cynomys is an Italian IoT company that patented sensors for monitoring over 30 parameters in livestock farms including welfare, emissions, and resource use. Launched in 2018 from Modena, the cloud-connected devices track temperature, humidity, feed intake, and ammonia levels for cattle, swine, and poultry operations. Cynomys serves feed producers and large farms in Italy, Spain, France, Netherlands, and Mexico, optimizing productivity and sustainability via remote dashboards. |
| HQ Country | |
| HQ City | Ronco Scrivia |
| Deal Date | 13 Mar 2024 |
| Round | Seed |
| Raised | $2M |
| Investors | Farming Future; PLUS9; DSM-Firmenich; SVG Ventures; Levante Capital |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all DSM-Firmenich investments and their VC round multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout DSM-Firmenich
| Who are competitors of DSM-Firmenich? | DSM-Firmenich main competitors include OMV, Qnity Electronics, Ningxia Baofeng Energy Group, Novonesis, PPG, Ems-Chemie, Wanhua Chemical, International Flavors & Fragrances, Rongsheng Petro Chemical, Dow. |
See public comps similar to DSM-Firmenich
Lists including DSM-Firmenich
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




